



Corporate Announcement

Neugenesis to present at New Cells for New Vaccines IV

Burlingame, California, October 11, 2009

Debbie Higgins, Director - Vaccine Research and Development at Neugenesis Corporation will be presenting at the IABS international workshop: New Cells for New Vaccines IV - Changing the Vaccine Landscape: Recombinant Systems to be held October 11-14, 2009 in Wilmington Delaware. The workshop will address progress on new substrates and recombinant systems for vaccine development currently approaching clinical trials including yeast, insect and plant cells. The Neugenesis presentation is titled "A rapid and inexpensive fungal production platform for producing influenza vaccine antigens".

About Neugenesis

Neugenesis Corporation is a privately held biotechnology company which has generated a diverse set of technology platforms for the world wide biotechnology and biopharmaceutical industry. In addition to its new position in vaccines, Neugenesis is also involved in development of technology for production of monoclonal antibodies for biodefense. The Company holds strong intellectual property positions in the areas of production of recombinant monoclonal antibodies, cell based gene-directed evolution, and cell based combinatorial biology. Neugenesis is actively seeking partners in the biopharmaceutical industry to rapidly move the technology into the marketplace.

Contact Information

Laurie Fosner
Neugenesis Corporation
863 Mitten Road, Suite C
Burlingame, CA 94101
(650) 689-2220
www.neugenesis.com.

###